Visibility Score
100/100
AI Mentions
641
AI Search Volume
340.4K
Impressions
0
As of May 19, 2026, Allucent (allucent.com) has an AI visibility score of 100 out of 100, based on 641 total AI mentions across platforms like Google AI Overview and ChatGPT. The brand generates 340.4K AI search volume and 0 impressions. On the traditional SEO side, Allucent receives an estimated 22.8K monthly organic visits with a traffic value of $127.4K. Compared to peers, Allucent ranks #1 of 5 in AI mention share of voice.
Allucent has 641 total AI mentions across 2 tracked platforms, generating 340.4K in AI search volume. Google AI Overview accounts for the largest share at 98% of mentions. AI platforms associate Allucent with 2 brand entities, including U.S. Food and Drug Administration, biomedical modeling field.
Sample questions where AI platforms cite Allucent in their responses.
A Biologics License Application (BLA) is a formal request submitted to the FDA's Center for Biologics Evaluation and Research (CBER) or CDER to market a new biological product (e.g., vaccines, blood products, gene therapies, mAbs) in the U.S.. It requires comprehensive data on safety, efficacy, and manufacturing, primarily using Form FDA 356h to demonstrate the product is safe, pure, and potent.123456
Key Components of a BLA
The BLA is organized into the Common Technical Document (CTD) structure:1
Key Aspects of the BLA Process
The BLA is regulated under 21 CFR 600–680, and the process includes a rigorous, multidisciplinary scientific review to ensure safety, purity, and potency.12
Allucent ranks for 2.9K organic keywords, driving an estimated 22.8K monthly visits worth $127.4K in traffic value. Organic traffic has grown from 105.9K to 120.6K over the tracked period. Top ranking keywords include "paediatric investigation plan" (position 68), "metabolites" (position 29), "rems" (position 20).
Organic Traffic
22.8K
estimated monthly visits
Organic Keywords
2.9K
ranking keywords
Traffic Value
$127.4K
estimated monthly value
Allucent ranks #1 out of 5 competitors in AI mention share of voice, capturing 85% of total mentions. Competitors tracked include Rho, ProSciento, Celerion, Nuvisan.
| Company | Mentions | AI Vol |
|---|
This is a static snapshot. Get live AI visibility tracking, competitor alerts, and actionable recommendations with VayoMed Brand Monitor.
| 15 |
| 0 |
| 5 | https://bioivt.com/blogs/what-is-adme-and-how-does-it-fit-into-drug-development#:~:text=ADME%20properties%20are%20a%20set%20of%20processes,loss%20of%20a%20substance%20from%20the%20system | 10 | 0 |
| 6 | https://www.allucent.com/resources/blog/intrinsic-and-extrinsic-factors-drug-development | 9 | 0 |
| 7 | https://www.allucent.com/resources/blog/what-are-regulatory-differences-between-nda-and-bla | 9 | 0 |
| 8 | https://www.ncbi.nlm.nih.gov/books/NBK557744/ | 9 | 0 |
| 9 | https://en.wikipedia.org/wiki/ADME | 8 | 0 |
| 10 | https://en.wikipedia.org/wiki/Pharmacodynamics | 8 | 0 |
A Biologics License Application (BLA) is a formal request submitted to the U.S. Food and Drug Administration (FDA) for permission to market and sell a new biological product (e.g., vaccines, gene therapies, monoclonal antibodies) across state lines . The BLA contains detailed preclinical/clinical data, manufacturing information, and product labeling, ensuring safety, purity, and potency.123
Key Components of a BLA Submission:
The BLA Process:
BLAs are distinct from New Drug Applications (NDAs) , as NDAs are used for small-molecule drugs rather than complex biological products.12
DDI is a versatile acronym that can refer to a unified network management solution, a telecommunications service, a data standards body, a leadership development consulting firm, a type of highway interchange, or drug-drug interaction studies.The correct meaning depends on the context, but the most common technical meaning is the integration of DNS, DHCP, and IPAM for network management.
Technology and networking
Business and consulting
Research and standards
Transportation
A metabolite is any small molecule (typically < 1.5 kDa) produced, consumed, or intermediate in metabolism —the chemical processes sustaining life. They are the products of digestion, energy conversion, and biosynthesis, including amino acids, vitamins, and organic acids. Metabolites also include the substances formed when drugs are broken down by the body.1234
Key Aspects of Metabolites
Clinical pharmacology is the scientific study of drugs in humans, focusing on the application of pharmacological principles—specifically pharmacokinetics (absorption, distribution, metabolism, excretion) and pharmacodynamics (drug effects)—to optimize patient care . It bridges laboratory research with clinical practice to improve medication efficacy, reduce side effects, and guide drug development, regulation, and personalized therapy.123
Key Aspects of Clinical Pharmacology
Stages of Clinical Pharmacology (Drug Development)
History and Evolution
The discipline developed alongside the need for stronger drug regulations, particularly following the thalidomide crisis in the 1960s, which highlighted the necessity of rigorous, evidence-based assessment of drug efficacy and safety.1
| Keyword | Position | Search Vol |
|---|---|---|
| paediatric investigation plan | 68 | 673.0K |
| metabolites | 29 | 110.0K |
| rems | 20 | 90.5K |
| cpms | 51 | 74.0K |
| good lab practices | 23 | 60.5K |
| topical topical | 19 | 49.5K |
| biologic license application | 14 | 40.5K |
| biologics license application | 4 | 40.5K |
| hais | 35 | 40.5K |
| healthcare associated infections | 31 | 40.5K |
| healthcare-associated infections | 35 | 40.5K |
| microbiome | 35 | 27.1K |
| antibodies monoclonal | 77 | 22.2K |
| clinical pharmacology | 11 | 22.2K |
| hospital-acquired infections | 73 | 22.2K |
| mab antibody | 41 | 22.2K |
| monoclonal antibodies | 27 | 22.2K |
| qtc | 20 | 22.2K |
| pharmacokinetic | 17 | 18.1K |
| pharmacokinetics | 11 | 18.1K |
| Impr. |
|---|
| Allucent (You) | 641 | 340.4K | 0 |
| Rho | 55 | 6.6K | 0 |
| ProSciento | 22 | 7.3K | 0 |
| Celerion | 19 | 2.9K | 0 |
| Nuvisan | 16 | 3.3K | 0 |